JPRN-UMIN000008631已完成2 期
Multi-center, phase II study for combination therapy with weekly pacritaxel and 5'-DFUR in patients with unresectable or recurrent gastric cancer - Multi-center, phase II study for combination therapy with weekly pacritaxel and 5'-DFUR in patients with unresectable or recurrent gastric cancer
Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine0 个研究点目标入组 45 人开始时间: 2012年8月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Drug hypersensitivity. 2) Infection and inflammation. 3) Prior infusion of paclitaxel 4) Peripheral neuropathy 5) Active synchronous malignancy. 6) Brain metastasis. 7) Severe mental disorders. 8) Symptomatic pulmonary fibrosis or interstitial pneumonia. 9) Severe systemic edema. 10) A large amount of pleural effusion or peritoneal fluid. 11) Severe heart disease. 12) Myocardial infarction within six months. 13) DM with insulin injection. 14) Pregnant patient
研究者
相似试验
已完成
2 期
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with metastatic gastric cancerElderly patients with metastatic gastric cancerJPRN-UMIN000009349ational Cancer Center Hospital40
已完成
2 期
Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)Colorectal cancerJPRN-UMIN000012063Kurume University Medical Center30
招募中
2 期
Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancercolorectal cancerJPRN-UMIN000006793ippon Medical School Musashikosugi Hospital40
尚未招募
2 期
Phase II clinical trial of multidisciplinary therapy using risk classification based on residual tumor volume and WHO grading for pediatric ependymoma patients (JCCG EPN1501)JPRN-UMIN000023803The Japan Children's Cancer Group(JCCG)40
已完成
2 期
A phase II study of TAS-102 and RamucirumabJPRN-jRCT2080224529Taiho Pharmaceutical Co., Ltd.60